Effect of surgical debulking on survival in Stage IV ovarian cancer

Gynecologic Oncology

Volumn 64, Issue 1, 1997, Pages 4-8

  Liu, Paul C ^a   Benjamin, Ivor ^a   Morgan, Mark A ^a   King, Stephanie A ^a   Mikuta, John J ^a   Rubin, Stephen C ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PACLITAXEL; PLATINUM DERIVATIVE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; FEMALE; FOLLOW UP; HISTOLOGY; HUMAN; LENGTH OF STAY; LIVER METASTASIS; MINIMAL RESIDUAL DISEASE; OVARY CANCER; PLEURA EFFUSION; PRIORITY JOURNAL; SECOND LOOK SURGERY; SURGICAL MORTALITY; SURVIVAL TIME;

EID: 0031033210     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1996.4396     Document Type: Article

References (21)

1. 1. Pettersson, F. International Federation of Gynecology and Obstetrics, Annual report on the results of treatment in gynecological cancer, Int. J. Obstet. Gynecol 21, 245 (1990).
2. 2. Griffiths, C. T. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma, Natl. Cancer Inst. Monogr. 42(101), 101-104 (1975).
3. 3. Griffiths, C. T., Parker, L. M., and Fuller, A. J. Role of cytoreductive surgical treatment in the management of advanced ovarian cancer, Cancer Treat. Rep. 63(2), 235-240 (1979).
4. 4. Delgado, G., Oram, D. H., and Petrilli, E. S. Stage III epithelial ovarian cancer: The role of maximal surgical reduction, Gynecol. Oncol. 18(3), 293-298 (1984).
5. 5. Hacker, N. F., Berek, J. S., Lagasse, L. D., Nieberg, R. K., and Elashoff, R. M. Primary cytoreductive surgery for epithelial ovarian cancer, Obstet. Gynecol. 61(4), 413-420 (1983).
6. 6. Omura, G., Bundy, B., Berek, J., Curry, S., Delgado, G., and Mortel, R. Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: A Gynecologic Oncology Group Study. J. Clin. Oncol. 7, 457-465 (1989).
7. 7. Piver, M. S., Lele, S. B., Marchetti, D. L., Baker, T. R., Tsukada, Y., and Emrich, L. J. The impact of aggressive debulking surgery and cisplatin-based chemotherapy on progression-free survival in stage III and IV ovarian carcinoma. J. Clin. Oncol. 6(6), 983-989 (1988).
8. 8. Benjamin, I., Noumoff, J. S., Carlson, J. A., Jr., Giuntoli, R. L., Morgan, M., and Mikuta, J. J. Database management for a gynecologic oncology service, Gynecol. Oncol. 38(3), 431-436 (1990).
9. 9. Kaplan, E., and Meier, P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 53, 457-481 (1958).
10. 10. Cox, D. Regression models and life tables, J. R. Stat. Soc. B. 34, 187-202 (1972).
11. 11. Cox, D. Analysis of binary data, Chapman and Hall, London (1970).
12. 12. Goodman, H. M., Harlow, B. L., Sheets, E. E., Muto, M. G., Brooks, S., Steller, M., Knapp, R. C., and Berkowitz, R. S. The role of cytoreductive surgery in the management of stage IV epithelial ovarian carcinoma, Gynecol. Oncol. 46(3), 367-371 (1992).
13. 13. Curtin, J., Malik, R., Venkatraman, E., Barakat, R., and Hoskins, W. Surgical Debulking of patients with stage IV ovarian cancer: Impact on survival, Gynecol. Oncol. 56, 129 (1995). [Abstract].
14. 14. Young, R., Chabner, B., Hubbard, S., Fisher, R., Bender, R., Anderson, T., Simon, R., Canellos, G., and DeVita, V. J. Advanced ovarian adenocarcinoma: A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy. N. Engl. J. Med. 299, 1261-1266 (1978).
15. 15. Wharton, J. T., and Herson, J. Surgery for common epithelial tumors of the ovary. Cancer 48, 582 (1981).
16. 16. Vogl, S., Pagano, M., Kaplan, B., Greenwald, E., Arseneau, J., and Bennett, B. Cisplatin based combination chemotherapy for advanced ovarian cancer: High overall response rate with curative potential only in women with small tumor burdens, Cancer 51, 2024-2030 (1983).
17. 17. Pohl, R., Dallenback-Hellweg, G., Plugge, T., and Czernobilsky, B. Prognostic parameters in patients with advanced ovarian malignant tumors. Eur. J. Gynaec. Oncol. 3, 160-169 (1984).
18. 18. Conte, P. F. A randomized trial comparing cisplatin, doxorubicin and cyclophosphamide in advanced ovarian cancer. J. Clin. Oncol. 4, 965 (1986).
19. 19. Guidozzi, F., and Ball, J. H. Extensive primary cytoreductive surgery for advanced epithelial ovarian cancer, Gynecol. Oncol. 53(3), 326-330 (1994).
20. 20. Hoskins, W. J., Bundy, B. N., Thigpen, J. T., and Omura, G. A. The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: A Gynecologic Oncology Group study, Gynecol. Oncol. 47(2), 159-166 (1992).
21. 21. Hoskins, W. J., McGuire, W. P., Brady, M. F., Homesley, H. D., Creasman, W. T., Berman, M., Ball, H., and Berek, J. S. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am. J. Obstet. Gynecol. 170(4), 974-979 (1994).